Abstract
Prostaglandin analogs (PGAs) are recommended as first-line therapy to lower intraocular pressure among glaucoma patients. Patients with lower rates of persistence could potentially have a higher risk of developing progressive visual loss. This study aims to compare persistence on latanoprostene bunod, latanoprost, bimatoprost, travoprost, and Beta Blockers, within a 12-month analysis period.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
